Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc.
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Istituto Oncologico Veneto IRCCS
Aulos Bioscience, Inc.
AstraZeneca
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
Neonc Technologies, Inc.
Replimune Inc.
Abramson Cancer Center at Penn Medicine
Melanoma Institute Australia
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
TuHURA Biosciences, Inc.
University of Arizona
Melanoma Institute Australia
Memgen, Inc.
University of Pittsburgh
Medicenna Therapeutics, Inc.
Marengo Therapeutics, Inc.
UNICANCER
Weill Medical College of Cornell University